A Phase 1 interventional study of DBV712 IHRP in Peanut Allergy, sponsored by DBV Technologies. Completed at 2 sites in United States. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-07-26.
Sponsored by DBV Technologies · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 5th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →
Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
This study's enrollment of 27 is below the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 105 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
13 studies in Peanut Hypersensitivity by DBV Technologies: none open now, 2 under way, 2 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 13 studies in Peanut Hypersensitivity by DBV Technologies, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 8th registered.
DBV Technologies’s Peanut Hypersensitivity studies by the year they started, since 2010.
1 of the studies testing palforzia in Peanut Hypersensitivity that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, from their registry updates:
Among DBV Technologies’s 13 in Peanut Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DBV712 In-House Reference Skin Prick Test preparation
Drug: DBV712 IHRP
DBV712 Solution for Skin Prick Test
Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)
Time frame: 1 day to 2 weeks
Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)
Time frame: Throughout the study (1 day to 2 weeks)
Ran from Nov 2017 to primary completion in Jun 2018, 7 months.
Of 14 phase 1 interventional studies under Peanut Hypersensitivity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 52. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palforzia
DBV Technologies